+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767307
  • Report
  • April 2019
  • Region: Global
  • 60 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Amgen Inc
  • ELC-Group
  • Gemphire Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Kastle Therapeutics LLC
  • Merck & Co Inc
  • MORE
The global clinical trial report- “2019 Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Homozygous Familial Hypercholesterolemia (HoFH). It presents in-depth analysis of Homozygous Familial Hypercholesterolemia (HoFH) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Homozygous Familial Hypercholesterolemia (HoFH).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Homozygous Familial Hypercholesterolemia (HoFH) clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Homozygous Familial Hypercholesterolemia (HoFH)

The research work is prepared through extensive and continuous research on Homozygous Familial Hypercholesterolemia (HoFH) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Homozygous Familial Hypercholesterolemia (HoFH) patients are identified
  • The report includes panorama of Homozygous Familial Hypercholesterolemia (HoFH) clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Homozygous Familial Hypercholesterolemia (HoFH) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amgen Inc
  • ELC-Group
  • Gemphire Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Kastle Therapeutics LLC
  • Merck & Co Inc
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials by Region
2.2.2 Average Enrollment of Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Homozygous Familial Hypercholesterolemia (HoFH) Treatment, 2019

3. Region wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials
3.1 Asia Pacific Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials by Country
3.2 Europe Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials by Country
3.3 North America Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials by Country
3.4 Middle East and Africa Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials by Country
3.5 South and Central America Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials by Country

4. Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trial Trends
4.1 Start Year wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials
4.2 Phase wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials
4.3 Trial Status wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials
4.4 Trial Type wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials

5. Homozygous Familial Hypercholesterolemia (HoFH) Average Enrollment Trends
5.1 Average Enrollment in Homozygous Familial Hypercholesterolemia (HoFH) Trials by Year
5.2 Average Enrollment in Homozygous Familial Hypercholesterolemia (HoFH) Trials by Phase
5.3 Average Enrollment in Homozygous Familial Hypercholesterolemia (HoFH) Trials by Status
5.4 Average Enrollment in Homozygous Familial Hypercholesterolemia (HoFH) Trials by Type of Trial

6. Companies Participating in Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials
6.1 Homozygous Familial Hypercholesterolemia (HoFH) Trials by Sponsor Type
6.2 Homozygous Familial Hypercholesterolemia (HoFH) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Homozygous Familial Hypercholesterolemia (HoFH) Trials- Phase 1
7.2 Homozygous Familial Hypercholesterolemia (HoFH) Trials- Phase 2
7.3 Homozygous Familial Hypercholesterolemia (HoFH) Trials- Phase 3
7.4 Homozygous Familial Hypercholesterolemia (HoFH) Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials and Enrolment
Figure 5: Europe - Country wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials and Enrolment
Figure 7: North America - Country wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials and Enrolment
Figure 9: Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials by Phase
Figure 10: Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials by Trial Status
Figure 11: Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials by Type
Figure 12: Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials by Sponsor Type
Figure 13: Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials by Leading Sponsors
Figure 14: Homozygous Familial Hypercholesterolemia (HoFH) Average Enrollment by Phase
Figure 15: Homozygous Familial Hypercholesterolemia (HoFH) Average Enrollment by Trial Status
Figure 16: Homozygous Familial Hypercholesterolemia (HoFH) Average Enrollment by Type
Figure 17: Homozygous Familial Hypercholesterolemia (HoFH)- Average Enrolment by Type of Sponsors
Figure 18: Homozygous Familial Hypercholesterolemia (HoFH)- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials and Enrolment
Table 5: Europe - Country wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials and Enrolment
Table 7: North America - Country wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Homozygous Familial Hypercholesterolemia (HoFH) Average Enrollment by Phase
Table 15: Homozygous Familial Hypercholesterolemia (HoFH) Average Enrollment by Trial Status
Table 16: Homozygous Familial Hypercholesterolemia (HoFH) Average Enrollment by Type
Table 17: Homozygous Familial Hypercholesterolemia (HoFH)- Average Enrolment by Type of Sponsors
Table 18: Homozygous Familial Hypercholesterolemia (HoFH)- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Amgen Inc
  • Dr. Reddy's Laboratories Ltd
  • ELC-Group
  • Gemphire Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Kastle Therapeutics LLC
  • Madrigal Pharmaceuticals Inc.
  • Merck & Co Inc
  • Novelion Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll